A new dawn for heart failure treatment?
Transatlantic Dialogues on Controversies in Contemporary Cardiology 2016, Rome
Co-morbities and humility
Dr. Marc Pfeffer (Boston, MA, USA) discusses how insights on the effect of antidiabetic drugs on CV outcomes has evolved over time, culminating in the benefit seen with empagliflozin on mortality and on heart failure. The latter benefit deserves more attention.
Brigham and Women’s Transatlantic Dialogues on Controversies in Contemporary Cardiology
This lecture is part of a special educational symposium exploring controversies in cardiovascular risk management and compared and contrasted best common practices and guidelines on both sides of the Atlantic. American and European experts discussed novel insights from basic and translational cardiovascular science in the context of ongoing and future clinical studies
The program is an initiative of research leaders from the Brigham and Women’s Hospital, Boston, USA in collaboration with the PACE foundation.
Marc A Pfeffer, MD - Victor J. Dzau Professor of Medicine Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Faculty did not receive an honorarium for their lectures